Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Revance Therapeutics Inc before investing.

In this article, we go over a few key elements for understanding Revance Therapeutics Inc’s stock price such as:

• Revance Therapeutics Inc’s current stock price and volume
• Why Revance Therapeutics Inc’s stock price changed recently
• Upgrades and downgrades for RVNC from analysts
• RVNC’s stock price momentum as measured by its relative strength

About Revance Therapeutics Inc (RVNC)

Before we jump into Revance Therapeutics Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings. The Company?s aesthetics portfolio of expertly created products and services, including DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, the RHA Collection of dermal fillers, and OPUL, the first-of-its-kind relational commerce platform for aesthetic practices. The Company?s therapeutics pipeline is focused on muscle movement disorders, including evaluating DAXXIFY in two debilitating conditions, cervical dystonia and upper limb spasticity. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient along with the other excipients. DAXXIFY a commercially approved product, is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Want to learn more about Revance Therapeutics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Revance Therapeutics Inc.

Revance Therapeutics Inc’s Stock Price as of Market Close

As of January 22, 2024, 4:00 PM, CST, Revance Therapeutics Inc’s stock price was $6.03.

Revance Therapeutics Inc is up 6.54% from its previous closing price of $5.66.

During the last market session, Revance Therapeutics Inc’s stock traded between $5.55 and $5.87. Currently, there are 86.61 million shares of Revance Therapeutics Inc stock available for purchase.

Unfortunately, Revance Therapeutics Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Revance Therapeutics Inc Stock Price History

Revance Therapeutics Inc’s (RVNC) price is currently down 31.4% so far this month.

During the month of January, Revance Therapeutics Inc’s stock price has reached a high of $9.75 and a low of $5.47.

Over the last year, Revance Therapeutics Inc has hit prices as high as $37.98 and as low as $5.47. Year to date, Revance Therapeutics Inc’s stock is down 67.33%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Revance Therapeutics Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 19, 2024, there were 2 analysts who downgraded Revance Therapeutics Inc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Revance Therapeutics Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Revance Therapeutics Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Revance Therapeutics Inc (RVNC) by visiting AAII Stock Evaluator.

Relative Price Strength of Revance Therapeutics Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 19, 2024, Revance Therapeutics Inc has a weighted four-quarter relative price strength of -35.07%, which translates to a Momentum Score of 8 and is considered to be Very Weak.

Want to learn more about how Revance Therapeutics Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Revance Therapeutics Inc Stock Price: Bottom Line

As of January 22, 2024, Revance Therapeutics Inc’s stock price is $6.03, which is up 6.54% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Revance Therapeutics Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.